Clinical trials: Juvenile Dermatomyositis (JDM)

Juvenile Dermatomyositis

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

• Recruiting
• Age: 5 to 17 years
• Phase 1

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and…

Trial name

NCT06569472

Testing

CD19-targetd CAR-T

Where

China

Volunteers

10 people

Sponsor

Chongqing Precision Biotech Co., Ltd